People: Catalyst Biosciences Inc (CBIO.OQ)
17 Jul 2019
Ms. Andrea Hunt is Director of the Company. Ms. Andrea Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology & Ophthalmology at Shire, Plc., where she was developing and integrating strategies for Shire's gene therapy platform. Ms. Hunt came to Shire through its acquisition of Baxalta, where she led the Global Blood Disorders Franchise within the Hematology Division. Prior to Baxalta, Ms. Hunt held several positions of increasing responsibility at Baxter Healthcare leading to her appointment as project leader to Baxter Healthcare's R&D program, BAX855, now Adynovate™. Ms. Hunt served on the board for the Alliance for Regenerative Medicine and is an advisor to the Angiogenesis Foundation. Ms. Hunt earned her MBA in marketing from the University of Michigan and her B.S. in hospital dietetics and B.A. in foods and nutrition from the University of Illinois.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|